Compare ADT Inc (ADT) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Bristol-Myers Squibb Co — how do they compare? ADT Inc trades at $7.31 (market cap $5.44B), while Bristol-Myers Squibb Co trades at $63.6 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 23.9× ADT Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ADT | BMY | |
|---|---|---|
Market Cap | $5.44B | $129.94B |
Sector | Industrials | Health |
52-Week High | $8.85 | $65.89 |
52-Week Low | $6.30 | $42.60 |
Enterprise Value | $13.13B | $163.92B |
Dividend Yield | 2.95% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.51, down 1.7% today, amid strong technical momentum with bullish moving averages and ADX signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.23 beating estimates of $0.22, and improving profitability with net margin reaching 11.86% in 2025. Recent news highlights ADT's Zacks upgrade to Buy and strong Q2 results with 18% operating cash flow growth.
ADT presents a compelling value opportunity with attractive valuation multiples (P/E 10.35, EV/EBITDA 4.93) and bullish analyst sentiment (47% Buy ratings). Key risks include high debt levels ($7.51B long-term debt) and competitive pressures in security services. The stock's technical strength and fundamental improvements support a positive near-term outlook, though investors should monitor debt management and industry competition.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
